Talzenna (talazoparib) with Xtandi (enzalutamide) - HRR-mutated metastatic castration-sensitive prostate cancer was approved by the FDA on October 26, 2026 for HRR gene-mutated metastatic castration-sensitive prostate cancer, with enzalutamide.
Verified against: FDA action day October 26, 2026 (FDA approval notification) · Announcement October 26, 2026 (Pfizer press release) · Goal date: none on record.
This page was first committed to pdufa.bio's public repository on Nov 20, 2026, 6:26 AM ET (public commit 0498681). Dates on this page are the FDA's and the sponsor's; this line is ours.
The FDA's notification states that on October 26, 2026 it approved talazoparib (Talzenna, Pfizer Inc.) with enzalutamide for adults with metastatic androgen pathway modulation-naive or -sensitive prostate cancer with HRR gene mutations detected by an FDA-authorized test (FDA, October 26, 2026). Pfizer announced the approval at 1:41 PM Eastern the same day (Pfizer's announcement). Pfizer had said the PDUFA action date fell in the last quarter of 2026 (Pfizer, July 22, 2026), a quarter rather than a day, so no early or late margin is given. Per the FDA, TALAPRO-3 (NCT04821622) randomized 599 patients; adding talazoparib to enzalutamide gave a radiographic progression-free survival hazard ratio of 0.48 (95% CI 0.36 to 0.65), with the median not reached versus 45.8 months. The application had Priority Review and was reviewed under Project Orbis.
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.
Primary source: FDA approval notification, October 26, 2026
FDA record of the action: the FDA approved on October 26, 2026, per FDA approval notification, October 26, 2026 (NDA 211651 supplement) (FDA notice). The sponsor announced it the same day. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.
Yes. The FDA approved talazoparib (Talzenna) with enzalutamide on October 26, 2026 for adults with metastatic androgen pathway modulation-naive or -sensitive prostate cancer with HRR gene mutations detected by an FDA-authorized test, per the FDA's own notification. Pfizer announced it the same day.
Talzenna (talazoparib) with Xtandi (enzalutamide) is a Pfizer Inc. (PFE) program. The FDA decision came on October 26, 2026; the company's own announcement is linked on this page.
PFE moved -0.8%, measured as the 2026-10-26 close against the 2026-10-23 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.
Pfizer's July 22, 2026 release gave the PDUFA action date only as the last quarter of 2026, so pdufa.bio does not publish an early or late margin. The FDA acted on October 26, 2026, inside that quarter.
Per the FDA, among 599 patients with HRR gene-mutated disease, adding talazoparib to enzalutamide cut the risk of radiographic progression or death (hazard ratio 0.48, 95% CI 0.36 to 0.65); median radiographic progression-free survival was not reached versus 45.8 months with placebo.